Indian Stocks Fall as RBI Hikes Rates to 5.50% 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
Iceland 4x4 Rental Guide: When Do You Really Need Four-Wheel Drive? 
Samsung, SK Hynix Shares Fall Ahead of Q3 Earnings 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Gold Prices Fall as Stronger Dollar Weighs on Bullion 
Thailand Plans Dual-Class Shares to Revive IPO Market 
Nasdaq Hits Record High as Tech Stocks Lift Wall Street 
Iran Tanker Attacks Surge as Hormuz Oil Flows Near Prewar Levels 
US Stock Futures Flat as Fed Minutes, Earnings Loom 
SpaceX Seeks $40 Billion for Nvidia AI Chips 
European Stocks Fall as Oil Rises Ahead of Fed Minutes 
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
S&P 500 Hits Record High as AI Rally Lifts Wall Street 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
HUTCHMED, AstraZeneca Seek FDA Approval for Lung Cancer Combo 
Add as a preferred source on Google
The Japanese Ministry of Health, Labor and Welfare has granted priority review status to the Alzheimer’s disease drug, lecanemab, of Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc.
Once the priority status has been granted, the target total review period is shortened.
Lecanemab was recently granted accelerated approval in the US.
A late-stage study showed the drug reduced the rate of cognitive decline in patients with early Alzheimer’s by 27 percent, compared with a placebo.
Similar experimental medications have largely all failed in the past.
Eisai also requested complete U.S. approval of the medication earlier this month. Food and Drug Administration (FDA) as a treatment for patients with neurodegenerative disease in its early stages.
